D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00047476
Recruitment Status : Completed
First Posted : October 9, 2002
Last Update Posted : June 24, 2005
Information provided by:

Brief Summary:
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.

Condition or disease Intervention/treatment Phase
Fatigue Neoplasms Drug: dexmethylphenidate(d-mph) Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients
Study Start Date : June 2002
Study Completion Date : March 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Diagnosis of cancer, excluding primary or metastatic brain tumors.
  • Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry.
  • Physical/neurological examination consistent with the absence of a focal neurological deficit
  • Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
  • Subjects must be able to adhere to the protocol requirements.
  • Subjects must understand and voluntarily sign an informed consent document.
  • Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00047476

United States, Alabama
Cooper Green Hospital, Jefferson Clinic
Birmingham, Alabama, United States, 35233
University of Alabama Palliative Care Institute
Birmingham, Alabama, United States, 35294-0023
United States, Arizona
Peak Performance Wellness
Flagstaff, Arizona, United States, 86004
Arizona Clinical Research Center
Tucson, Arizona, United States, 85712
United States, California
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States, 94704
California Cancer Care Inc
Greenbrae, California, United States, 94904-2007
Clinical Trials and Research Associates
Montebello, California, United States, 90640
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States, 92262
United States, Florida
Comprehensive Cancer Center
Boca Raton, Florida, United States, 33428
Osler Clinical Research/Osler Medical Inc
Melbourne, Florida, United States, 32901
University of Miami, Sylvester Cancer Research Center
Miami, Florida, United States, 33139
Cancer Research Network Inc
Plantation, Florida, United States, 33324
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33162
United States, Georgia
Piedmont Hospital
Atlanta, Georgia, United States, 30309
United States, Kentucky
Markey Cancer Center
Lexington, Kentucky, United States, 40536
United States, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
United States, New York
Beth Israel Cancer Center
New York, New York, United States, 10003
United States, South Carolina
Gynecologic Oncology Associates and Development LLC
Greenville, South Carolina, United States, 29604
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023
Northwest Medical Specialists, PLLC
Tacoma, Washington, United States, 98405
United States, Wisconsin
UW Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792-6164
Sponsors and Collaborators
Celgene Corporation Identifier: NCT00047476     History of Changes
Obsolete Identifiers: NCT00052533
Other Study ID Numbers: d-MPH-COG-002
First Posted: October 9, 2002    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: May 2004

Keywords provided by Celgene:
neurobehavioral function
chemo brain
memory loss
trouble concentrating

Additional relevant MeSH terms:
Signs and Symptoms
Dexmethylphenidate Hydrochloride
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents